Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]T807 PET Imaging for Tau in Alzheimer's Disease
NCT02370524Phase 1Completed
- Sponsor
- Molecular NeuroImaging
- Start
- Jan 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flortaucipir in Alzheimer's disease (AD), sponsored by Molecular NeuroImaging. Primary endpoint: Quantitative evaluation of [18F]T807 for imaging Tau at 1 year. Started Jan 2015; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02370524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370524.